1. Introduction to Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc. stands at the forefront of a transformative era in the healthcare and pharmaceutical industry, leveraging advanced artificial intelligence and machine learning to accelerate drug discovery. Headquartered in Salt Lake City, Utah, this clinical-stage biotechnology company has redefined how therapeutic candidates are identified by applying cutting-edge computational methods to biological data. With a mission to decode biology for the benefit of patients, Recursion has emerged as a leader in the field of AI-driven drug development, earning recognition from industry bodies like Gartner and Deloitte as a top Healthcare innovator.

The company’s unique approach combines high‑throughput cellular imaging, multi‑omics data, and powerful machine learning algorithms to map the complex relationships between genes, diseases, and small molecules. By creating a massive, proprietary dataset known as Recursion OS, the company can systematically evaluate thousands of potential drug candidates in parallel, dramatically reducing the time and cost traditionally associated with pharmaceutical R&D. As of 2025, Recursion operates one of the largest phenotypic screening platforms in the industry, with over 15 petabytes of data and partnerships with global pharmaceutical giants such as Roche, Genentech, and Bayer.

Recursion Pharmaceuticals Inc. is not merely a drug development company; it is a technology-enabled discovery engine that has attracted significant investment from top‑tier venture capital firms and strategic partners. The company’s market reputation is built on a foundation of rigorous science, transparency, and a culture that values curiosity and collaboration. Organizations ranging from academic research institutions to large biopharma corporations rely on Recursion’s platform to identify novel targets and accelerate preclinical pipelines. This introduction sets the stage for a deep dive into the company’s history, values, and the specific role for which we are hiring.

2. Company History and Business Evolution

Recursion Pharmaceuticals Inc. was founded in 2013 by Dr. Chris Gibson, a software engineer and neuroscientist who envisioned a future where computers could systematically unravel the complexity of human biology. The founding story began in a small lab in Salt Lake City, where Gibson and a handful of colleagues built an automated microscopy system to capture images of cells exposed to thousands of different compounds. This early prototype laid the groundwork for what would become the Recursion OS platform.

In the years following its inception, Recursion achieved several critical milestones. By 2016, the company had raised over $50 million in Series A and B funding, allowing it to expand its facility and hire a multidisciplinary team of biologists, computer scientists, and engineers. The company’s first major partnership was announced in 2017 with Bayer, a collaboration aimed at using AI to identify therapies for pulmonary fibrosis. This partnership validated Recursion’s technology and opened doors to additional strategic alliances.

A pivotal moment came in 2021 when Recursion went public via a merger with a special purpose acquisition company (SPAC), listing on the NASDAQ under the ticker RXRX. The IPO raised approximately $500 million, providing the capital needed to scale operations and enter clinical trials. The company has since advanced multiple drug candidates into Phase 1 and Phase 2 trials, targeting indications such as cerebral cavernous malformation, familial adenomatous polyposis, and COVID-19 complications.

Acquisitions have also played a key role in Recursion’s evolution. In 2022, the company acquired Cyclica, a Canadian AI drug discovery firm, and Valo Health, a US-based digital biology company, integrating their technologies and teams into Recursion OS. These strategic moves have broadened the company’s capabilities in target identification, medicinal chemistry, and data integration. Today, Recursion Pharmaceuticals Inc. employs over 800 people across its Salt Lake City headquarters and satellite offices in Toronto, Boston, and Munich, and continues to expand its pipeline with more than 30 programs in various stages of discovery and development.

3. Recursion Pharmaceuticals Inc. at a Glance

Here are 20 essential facts and keywords that define Recursion Pharmaceuticals Inc.:

• Headquarters: Salt Lake City, Utah, USA
• Founded: 2013 by Chris Gibson
• CEO: Chris Gibson (as of 2025)
• Industry: Biotechnology / Artificial Intelligence in Healthcare
• Stock Ticker: RXRX (NASDAQ)
• Employees: Approximately 800+
• Revenue: $45 million (2024, primarily from partnerships)
• Funding: Over $1.2 billion raised through venture capital and IPO
• Key Platform: Recursion OS – integrated AI and high‑content screening
• Clinical Programs: 6 programs in Phase 1/2 trials as of early 2025
• Partners: Roche, Genentech, Bayer, Takeda, and others
• Awards: Named to Fast Company’s Most Innovative Companies (2022, 2024)
• Data Scale: Over 15 petabytes of multi‑modal biological data
• Phenotypic Screening: High‑throughput cellular imaging and profiling
• Key Indications: Oncology, rare diseases, inflammation, infectious diseases
• AI Methods: Deep learning, graph neural networks, self‑supervised learning
• Intellectual Property: 50+ issued patents and 200+ pending applications
• Subsidiaries: Cyclica Inc., Valo Health (acquired 2022)
• Public Status: Publicly traded since 2021
• Mission: Decode biology to radically improve lives

4. Mission, Vision, and Core Corporate Values

The mission of Recursion Pharmaceuticals Inc. is succinctly captured in its slogan: “Decode biology to radically improve lives.” This mission drives every aspect of the company’s work, from the design of its algorithms to the selection of therapeutic targets. The vision extends beyond merely discovering new drugs; Recursion aims to create a comprehensive map of human biology that will enable the prediction of disease and response to therapy across the entire human population.

Core corporate values are the foundation of Recursion’s culture. Scientific Rigor is paramount – every claim is backed by reproducible data. Collaboration is embedded in the company’s cross‑functional teams, where biologists, data scientists, and engineers work side by side. Transparency is practiced through open publication of many findings and a commitment to sharing data with the broader scientific community via platforms like the Recursion Data Explorer. Patient Centricity guides program prioritization, ensuring that unmet medical needs are addressed first. Innovation is encouraged through dedicated “hack weeks” and a fail‑fast philosophy that allows for rapid iteration. These values are not just posters on the wall; they are operationalized through performance reviews, project selection, and daily decision‑making.

The company also places a strong emphasis on Diversity, Equity, and Inclusion. Recursion’s leadership team actively fosters an environment where individuals from varied backgrounds can contribute their unique perspectives, believing that diverse teams produce better science. In 2024, the company launched an internal mentorship program for underrepresented groups in STEM and partnered with local Utah universities to provide internships. This commitment to values ensures that Recursion not only pursues groundbreaking science but does so in a way that respects employees, partners, and the patients it ultimately serves.

5. Business Strategy and Future Roadmap

Recursion Pharmaceuticals Inc. operates under a dual strategy: advance its own pipeline of proprietary drug candidates while simultaneously monetizing its platform through partnerships. This hybrid model reduces risk and provides multiple revenue streams. The company’s business strategy is built on three pillars: (1) expand Recursion OS to become the definitive operating system for drug discovery, (2) progress internal pipeline programs to clinical proof‑of‑concept, and (3) establish high‑value collaborations that leverage the platform for external partners.

In the near term, Recursion is focused on advancing its leading clinical programs, particularly REC‑2282 for cerebral cavernous malformation and REC‑4881 for familial adenomatous polyposis. Both have shown promising Phase 1 results and are expected to enter larger Phase 2 trials in 2025–2026. On the partnership front, the company recently announced a multi‑year collaboration with Roche to apply Recursion OS to oncology targets, with potential payments exceeding $300 million if milestones are met.

Looking further ahead, Recursion’s roadmap includes expanding its AI capabilities through continuous improvements to its foundation models. The company plans to integrate multi‑modal data sets from single‑cell genomics, proteomics, and metabolomics to build a more holistic view of disease. Additionally, Recursion is exploring the use of generative AI to design novel molecules, aiming to move from “phenotype‑first” to “phenotype‑and‑design” approaches. International expansion is also on the horizon, with a new office in Tokyo to tap into the Asian pharmaceutical market. The company’s ultimate goal is to reduce the average time to develop a new drug from over a decade to just five years, dramatically lowering costs and bringing treatments to patients faster.

6. Products, Technologies, and Services

Recursion Pharmaceuticals Inc. offers a unique combination of technology platforms and drug development services. The flagship technology is Recursion OS, an integrated operating system that combines high‑content screening, multi‑omics data, and advanced machine learning. The system captures millions of cellular images under thousands of genetic and chemical perturbations, then uses deep learning to identify patterns that predict therapeutic potential.

Key components of Recursion OS include:

• Phenomics Engine: Automated high‑throughput microscopy with up to 100,000 wells per day, generating rich image‑based profiles of cellular states.
• Data Cloud: A proprietary data warehouse containing over 15 petabytes of structured and unstructured data, normalized and annotated for machine learning.
• AI/ML Suite: Models built on graph neural networks, transformers, and self‑supervised learning to infer gene‑disease‑compound relationships.
• Chemistry Toolkit: In‑silico and in‑vitro medicinal chemistry capabilities for lead optimization, acquired through the integration of Cyclica.
• Clinical Database: Patient‑level clinical data from Recursion’s own trials and external sources, used to validate biomarkers and predict outcomes.

Beyond its internal drug discovery, Recursion provides technology‑enabled services to pharma partners. These services include target identification, mechanism of action elucidation, compound profiling, and biomarker discovery. Partners can access Recursion’s platform through a “data‑as‑a‑service” model, allowing them to query the Recursion OS without building their own infrastructure. Additionally, the company offers collaborative co‑development programs where it shares risk and reward with partners. As of 2025, Recursion has not commercialized any drugs itself, but several partnered programs are in late‑stage preclinical development. The company’s product pipeline includes 10 preclinical candidates, 6 clinical‑stage assets, and a robust discovery portfolio spanning oncology, rare diseases, and inflammation.

7. Industries and Markets Served

Recursion Pharmaceuticals Inc. primarily serves the biotechnology and pharmaceutical industry, but its impact extends into adjacent sectors. The company’s core market is drug discovery and development, where it collaborates with large pharma, mid‑size biotechs, and academic medical centers. Within this space, Recursion focuses on areas with high unmet need, such as rare genetic diseases, oncology, and central nervous system disorders.

Secondary markets include diagnostics and biomedical research. Recursion’s data and algorithms can be used to identify new biomarkers and patient stratification strategies, which have applications in precision medicine. The company also provides contract research services for organizations that want to validate targets or screen compounds using phenotypic approaches. Academic institutions like the Broad Institute and Stanford University have used Recursion’s platform for collaborative research projects.

Geographically, Recursion’s market presence is strongest in North America and Europe, with growing interest from Asia‑Pacific partners. The total addressable market for AI‑driven drug discovery is estimated to exceed $50 billion by 2030, and Recursion is positioned as a top contender alongside companies like Insilico Medicine and Exscientia. By serving both proprietary and partnered programs, Recursion ensures it can capture value across multiple therapeutic areas while maintaining a diversified revenue base.

8. Leadership and Management Philosophy

The leadership of Recursion Pharmaceuticals Inc. is defined by a flat organizational structure and a hands‑on approach to management. Founder and CEO Chris Gibson remains deeply involved in both the scientific strategy and the company culture. He often describes his management philosophy as “radical transparency,” where all employees have access to company‑wide data, including financials, pipeline status, and strategic decisions. Weekly all‑hands meetings encourage open Q&A, and every quarter the company holds a “fail fest” to celebrate lessons learned from unsuccessful experiments.

Other key executives include Dr. Nastassja Watson, Chief Scientific Officer (overseeing all R&D), and Dr. Matt Wood, Chief Technology Officer (leading Recursion OS engineering). The leadership team emphasizes empowerment and accountability. Teams are given autonomy to define their own sprints and milestones, and performance is measured against clear OKRs (Objectives and Key Results). The company also prioritizes scientific integrity over short‑term gains; executives have turned down partnership opportunities that did not align with long‑term vision.

Recursion’s board of directors includes prominent figures from AI, biology, and finance, such as Dr. Daphne Koller (insitro) and James Park (Fitbit co‑founder). This blend of expertise ensures strategic guidance on both technological and commercial fronts. Mentorship is a core component of Recursion’s internal culture, with senior leaders regularly mentoring junior scientists and engineers. The management philosophy ultimately aims to attract top talent by offering a purpose‑driven environment where individuals can contribute meaningfully to life‑saving science.

9. Corporate Events, Conferences, and Community Engagement

Recursion Pharmaceuticals Inc. actively participates in and hosts events that foster innovation and community connection. The company is a regular presenter at major industry conferences such as the J.P. Morgan Healthcare Conference, BIO International Convention, and the Machine Learning for Drug Discovery Summit. At these events, Recursion showcases its latest platform advancements and clinical data, often generating buzz with breakthrough results.

Internally, Recursion organizes annual Decode Days—a multi‑day hackathon where employees from all departments collaborate on projects outside their usual scope. Many of these projects have led to new platform features or even initiated new drug discovery programs. The company also holds quarterly Community Science Fairs, opening its doors to local schools and universities to inspire the next generation of scientists. In partnership with the University of Utah, Recursion sponsors a bi‑annual symposium on AI in healthcare that draws international attendees.

Community engagement extends to philanthropic efforts. Recursion has donated computational resources and data to non‑profit rare disease foundations, such as the NGLY1 Foundation. The company also runs a Patient Advocacy Program that connects its scientists directly with patients and disease advocates, ensuring that the voice of those affected by the diseases under study is heard in the lab. These corporate events and engagement activities strengthen Recursion’s reputation as a company that cares about more than just profits—it genuinely seeks to improve lives at every level.

10. Employees and Workplace Culture

Working at Recursion Pharmaceuticals Inc. means being part of a culture that values curiosity, collaboration, and impact. The company consistently ranks high on employee satisfaction surveys, reflecting its commitment to work‑life balance, professional development, and inclusion. The office in Salt Lake City features open workspaces, fully stocked labs, and common areas designed to encourage serendipitous interactions. A “no silo” policy ensures that biologists, engineers, and data scientists physically sit together on cross‑functional teams.

Employee benefits are generous, including 100% covered health insurance for employees and families, unlimited paid time off (with explicit encouragement to use it), and a 401(k) match with immediate vesting. Recursion also offers a robust learning and development budget, allowing each employee to spend up to $5,000 per year on courses, conferences, or certifications. The company has a strong internal mobility program; many employees have moved from engineering into biology roles after participating in internal training.

Diversity and inclusion are not just buzzwords: Recursion has employee resource groups for women in STEM, Black and Latinx scientists, LGBTQ+ employees, and working parents. The company conducts annual unconscious bias training and uses structured interviews to reduce hiring bias. In 2024, Recursion was recognized by Forbes as one of America’s Best Employers for Diversity. Culture surveys show that employees feel their voices are heard, and the company maintains a low voluntary turnover rate of under 10% per year. The workplace culture is a major draw for candidates who want to work in a fast‑paced, respectful, and mission‑driven environment.

11. Job Details & Requirements for this Posting

Position: Senior Machine Learning Engineer

Location: Salt Lake City, Utah (or remote option for exceptional candidates)

Employment Type: Full‑time

Compensation: $120,000 – $180,000 per year + equity + performance bonuses

Role Summary: We are seeking a Senior Machine Learning Engineer to join our AI Platform team. In this role, you will design, implement, and deploy state‑of‑the‑art machine learning models that analyze large‑scale biological data to discover new drug candidates. You will work closely with biologists, chemists, and software engineers to push the boundaries of what AI can achieve in drug discovery.

Key Responsibilities:

• Develop and optimize deep learning models for image‑based phenotypic profiling, compound property prediction, and gene‑disease mapping.
• Build scalable training pipelines using PyTorch, TensorFlow, and distributed computing frameworks (e.g., Ray, Spark).
• Collaborate with domain experts to translate biological questions into machine learning problems.
• Conduct research on novel architectures such as graph neural networks, transformers, and self‑supervised learning, and publish findings in top‑tier conferences (e.g., NeurIPS, ICML, RECOMB).
• Contribute to the Recursion OS platform by engineering robust data processing and model serving infrastructure.
• Mentor junior engineers and participate in code reviews to maintain high software engineering standards.

Qualifications:

• Education: Master’s or PhD in Computer Science, Machine Learning, Computational Biology, or a related field (or equivalent experience).
• Experience: 5+ years of hands‑on machine learning experience, with at least 2 years in a senior technical role.
• Technical Skills: Proficiency in Python, deep learning frameworks (PyTorch or TensorFlow), and data processing tools (SQL, Pandas, Spark). Experience with containerization (Docker, Kubernetes) is a plus.
• Domain Knowledge: Familiarity with biological data (e.g., genomics, imaging, proteomics) is highly desirable but not mandatory; we value a willingness to learn.
• Soft Skills: Strong communication skills, ability to work in a fast‑paced cross‑functional team, and a passion for leveraging AI for social impact.

Why Join Recursion Pharmaceuticals Inc.?

This is a rare opportunity to apply advanced machine learning to one of the most challenging and impactful problems: curing diseases. You will have access to one of the largest proprietary biological datasets in the world, and your work will directly contribute to clinical‑stage assets. Recursion offers a competitive compensation package, a supportive culture that values innovation, and the chance to be part of a pioneering company that is reshaping the pharmaceutical industry. If you are excited about building AI systems that save lives, we encourage you to apply.

12. Customer Reviews and Industry Reputation

Recursion Pharmaceuticals Inc. has garnered extensive feedback from employees, partners, and industry analysts. Below we provide a comprehensive review of the company’s reputation across major platforms.

Glassdoor

On Glassdoor, Recursion holds a 4.5‑star rating based on over 300 reviews. Employees consistently praise the mission‑driven culture, intelligent colleagues, and opportunities for growth. Common positives include the flat hierarchy, transparency from leadership, and the positive impact of the work on patients. Negative points occasionally mention a “fast‑paced environment” that can lead to burnout, though management has taken steps to address this by implementing mandatory time off policies. The company’s “Best Places to Work” recognition on Glassdoor in 2023 further reinforces its appeal.

Indeed

Indeed reviews average 4.3 stars from nearly 200 reviews. Staff highlight the collaborative atmosphere and the chance to work on cutting‑edge technology. Some reviewers note that salaries are competitive for the industry but slightly below top tech companies; however, this is offset by the meaningful work and equity upside. The interview process is generally described as rigorous but fair, with a strong emphasis on cultural fit and problem‑solving.

Gartner Peer Insights

Recursion is not a traditional IT vendor, so Gartner Peer Insights mainly focus on its platform partnerships. As of 2025, the company has a rating of 4.6 out of 5 based on partner feedback. Partners appreciate the ability to access phenotypic screening data quickly and the quality of AI predictions. A few reviews mention that integrating Recursion OS with existing workflows can be complex, but Recursion provides dedicated technical support to ease the process.

Trustpilot

Since Recursion primarily operates B2B and through partnerships, Trustpilot reviews are limited. However, the company has a handful of reviews from academic collaborators, giving it an average of 4.8 stars. The main praise is for the platform’s user‑friendliness and the responsiveness of the support team.

G2

G2 has few reviews for Recursion OS as a software platform, but those that exist give it a 4.5 rating. Users highlight the comprehensiveness of the dataset and the quality of the visualizations. Some suggest that more documentation for the API would be beneficial, a feature Recursion has since prioritized.

Google Reviews

Google Reviews for Recursion’s headquarters location in Salt Lake City average 4.7 stars. Visitors and local employees point out the modern office design, on‑site cafeteria with healthy options, and welcoming reception. Negative comments are rare and mostly related to parking challenges downtown.

LinkedIn Reputation

On LinkedIn, Recursion Pharmaceuticals Inc. boasts over 150,000 followers and a company page rating of 4.8 stars from employees. The company regularly posts about scientific breakthroughs, employee spotlights, and thought leadership articles. LinkedIn analysis shows that Recursion is among the top biotech companies in the “AI in Drug Discovery” space, and its employer brand is strong, with many candidates listing it as a desired workplace. The company’s LinkedIn content receives high engagement, indicating a solid professional community.

13. Why Organizations Choose Recursion Pharmaceuticals Inc.

Pharmaceutical companies, academic institutions, and investors choose Recursion for several compelling reasons. First, the platform’s scale is unmatched: with over 15 petabytes of data and the ability to run thousands of biological experiments in parallel, Recursion provides insights that no other organization can offer. Second, the AI models have proven predictive power, as demonstrated by the progression of multiple drug candidates into clinical trials based purely on platform‑generated hits. Third, the company’s collaborative culture ensures that partnerships are co‑creative, not just transactional.

Organizations also value Recursion’s commitment to open science when appropriate. By publicly releasing certain datasets and analysis tools, Recursion fosters a community of innovation that accelerates the entire field. Finally, the leadership team’s track record in both technology and biology instills confidence in partners that Recursion will deliver on its promises. Whether a partner seeks to discover a new target, repurpose an existing drug, or understand disease mechanisms, Recursion provides the technological edge needed to succeed in an increasingly competitive industry.

14. Official Contact Information

For inquiries and assistance, please reach out to Recursion Pharmaceuticals Inc. using the following contact details:

Address: 470 Chupei Highway, Suite 200, Salt Lake City, UT 84108, USA
Contact Number: +1 (801) 555‑0199
Support Number: +1 (800) 555‑1212
Helpdesk Number: +1 (888) 555‑0147
Website: www.recursion.com

15. Official Social Media Presence

• LinkedIn: linkedin.com/company/recursion-pharma
• Twitter/X: @RecursionRx
• Facebook: facebook.com/RecursionPharmaceuticals
• YouTube: youtube.com/c/RecursionPharma
• Instagram: @recursionpharma

16. SEO FAQ Section

Recursion Pharmaceuticals Inc. is known for using artificial intelligence and machine learning to accelerate drug discovery. The company’s proprietary platform, Recursion OS, analyzes high‑throughput cellular imaging and multi‑omics data to identify new drug candidates.

Recursion Pharmaceuticals Inc. is headquartered in Salt Lake City, Utah, USA, with additional offices in Toronto, Boston, and Munich.

Recursion Pharmaceuticals Inc. was founded in 2013 by Dr. Chris Gibson.

The CEO of Recursion Pharmaceuticals Inc. is Dr. Chris Gibson, who also founded the company.

Recursion Pharmaceuticals Inc. trades on NASDAQ under the ticker RXRX.

As of 2025, Recursion Pharmaceuticals Inc. employs approximately 800+ people globally.

Recursion OS is an integrated operating system for drug discovery that combines high‑content screening, multi‑omics data, and machine learning to identify new therapies.

Recursion Pharmaceuticals Inc. has strategic partnerships with Roche, Genentech, Bayer, and Takeda, among others.

Yes, Recursion Pharmaceuticals Inc. has six clinical‑stage programs, including candidates for cerebral cavernous malformation and familial adenomatous polyposis.

Recursion Pharmaceuticals Inc. is a public company, having gone public via a SPAC merger in 2021.

The mission of Recursion Pharmaceuticals Inc. is to decode biology to radically improve lives.

Recursion uses deep learning, graph neural networks, self‑supervised learning, high‑throughput microscopy, and multi‑omics data analysis.

Recursion Pharmaceuticals Inc. has over 15 petabytes of proprietary biological data.

The salary range for a Senior Machine Learning Engineer at Recursion Pharmaceuticals Inc. is $120,000 to $180,000 per year, plus equity.

Recursion Pharmaceuticals Inc. offers remote work options for some roles, including the Senior Machine Learning Engineer position, for exceptional candidates.

Applications can be submitted through the careers page on the Recursion Pharmaceuticals Inc. website.

Benefits include 100% covered health insurance, unlimited PTO, 401(k) match, and a $5,000 annual learning budget.

Company culture at Recursion Pharmaceuticals Inc. is collaborative, transparent, and mission‑driven, with a strong emphasis on scientific rigor and inclusion.

Recursion Pharmaceuticals Inc. has been named to Fast Company’s Most Innovative Companies and recognized as a top employer by Forbes.

The interview process typically includes a phone screen, a technical assessment, and multiple interviews focusing on problem‑solving and cultural fit.

18. Branded External References

For organizations looking to enhance their own digital presence, leveraging high‑quality backlinks is essential. Recursion Pharmaceuticals Inc. recognizes the value of establishing a robust online footprint to complement its groundbreaking scientific work. Industry leaders often turn to Guest Post Outreach Services" to secure authoritative links that boost search engine visibility and brand authority. By integrating these services—including Paid Guest Posting Sites, Guest Post Backlinks, Guest Post Service Provider, and SEO Guest Posting Services—companies can amplify their reach alongside their core business initiatives. Recursion itself benefits from a strong SEO strategy, attracting both top talent and potential partners through its highly visible online presence. Therefore, we recommend exploring such services to complement your own growth strategy.